Projects / Programmes source: ARIS

Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih (Slovene)

Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
3.01  Medical and Health Sciences  Basic medicine 
Evaluation (rules)
source: COBISS
Researchers (49)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  15490  PhD Pegi Ahlin Grabnar  Pharmacy  Researcher  2009 - 2013  207 
2.  15104  PhD Saša Baumgartner  Pharmacy  Researcher  2009 - 2013  306 
3.  25492  PhD Katja Berginc  Pharmacy  Researcher  2009 - 2013  77 
4.  11124  PhD Marija Bogataj  Pharmacy  Researcher  2009 - 2013  372 
5.  17432  Margareta Cof    Technical associate  2009 - 2013 
6.  26494  PhD Andrej Dolenc  Pharmacy  Junior researcher  2009  12 
7.  21455  PhD Rok Dreu  Pharmacy  Researcher  2009 - 2013  292 
8.  34509  PhD Mateja Egart  Pharmacy  Junior researcher  2011 - 2013  15 
9.  18700  Valerija Garb    Technical associate  2009 - 2013 
10.  11789  PhD Mirjana Gašperlin  Pharmacy  Researcher  2009 - 2013  598 
11.  28446  PhD Ilija German Ilić  Pharmacy  Researcher  2009 - 2013  141 
12.  29887  PhD Mirjam Gosenca Matjaž  Pharmacy  Researcher  2012 - 2013  138 
13.  16107  PhD Iztok Grabnar  Pharmacy  Researcher  2009 - 2013  435 
14.  17433  Tatjana Hrovatič    Technical associate  2009 - 2013 
15.  34670  PhD Biljana Janković  Pharmacy  Researcher  2012 - 2013  136 
16.  12942  PhD Janez Kerč  Pharmacy  Researcher  2009 - 2013  240 
17.  20370  PhD Mojca Kerec Kos  Pharmacy  Researcher  2009 - 2013  237 
18.  18699  Mojca Keržan    Technical associate  2009 - 2013 
19.  01466  PhD Vojko Kmetec  Pharmacy  Researcher  2009 - 2012  193 
20.  24402  PhD Petra Kocbek  Pharmacy  Researcher  2009 - 2013  291 
21.  17434  Mihaela Kolarev    Technical associate  2009 - 2013 
22.  20374  PhD Mitja Kos  Pharmacy  Researcher  2009 - 2013  481 
23.  30818  PhD Eva Kralj  Pharmacy  Junior researcher  2009 - 2013  18 
24.  33296  PhD Ana Krese  Pharmacy  Junior researcher  2010 - 2013  10 
25.  11122  PhD Albin Kristl  Pharmacy  Researcher  2009 - 2013  350 
26.  09032  PhD Julijana Kristl  Pharmacy  Researcher  2009 - 2013  932 
27.  32037  PhD Zoran Lavrič  Pharmacy  Junior researcher  2009 - 2013  67 
28.  17430  Nevenka Lilik    Technical associate  2009 - 2013 
29.  24399  PhD Igor Locatelli  Pharmacy  Researcher  2009 - 2013  273 
30.  35433  PhD Nika Marđetko  Public health (occupational safety)  Junior researcher  2012 - 2013  36 
31.  06086  PhD Aleš Mrhar  Pharmacy  Head  2009 - 2013  1,161 
32.  36441  PhD Urška Nabergoj Makovec  Pharmacy  Junior researcher  2013  61 
33.  26510  PhD Nataša Nagelj Kovačič  Pharmacy  Junior researcher  2009 - 2013  16 
34.  25489  PhD Marko Obradović  Pharmacy  Junior researcher  2009  30 
35.  33909  PhD Jan Pelipenko  Pharmacy  Junior researcher  2011 - 2013  44 
36.  33336  PhD Mitja Pišlar  Pharmacy  Junior researcher  2010 - 2013  29 
37.  14935  PhD Odon Planinšek  Pharmacy  Researcher  2009 - 2013  437 
38.  32039  PhD Romana Rošic Danko  Pharmacy  Junior researcher  2009 - 2013  43 
39.  23549  PhD Robert Roškar  Pharmacy  Researcher  2010 - 2013  301 
40.  25488  Branka Rozman  Pharmacy  Junior researcher  2009  22 
41.  09031  PhD Stanko Srčič  Pharmacy  Researcher  2009 - 2013  675 
42.  28860  PhD Karmen Teskač Plajnšek  Pharmacy  Junior researcher  2009 - 2011  50 
43.  30817  PhD Tina Trdan Lušin  Natural sciences and mathematics  Junior researcher  2009 - 2013  38 
44.  23420  PhD Jurij Trontelj  Pharmacy  Researcher  2009 - 2013  254 
45.  18155  PhD Tomaž Vovk  Pharmacy  Researcher  2009 - 2013  227 
46.  08333  PhD Franc Vrečer  Pharmacy  Researcher  2009 - 2013  397 
47.  36439  PhD Špela Zupančič  Pharmacy  Junior researcher  2013  127 
48.  26226  PhD Alenka Zvonar Pobirk  Pharmacy  Researcher  2009 - 2013  209 
49.  22659  PhD Simon Žakelj  Pharmacy  Researcher  2009 - 2013  162 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0787  University of Ljubljana, Faculty of Pharmacy  Ljubljana  1626973  17,522 
Significance for science
This research program can be viewed as a part of contemporary scientific trends in the field of development and evaluation of new safe and effective medicines with the purpose to decrease interindividual variability and increase effectiveness of therapy. Different approaches were studied using chosen model drugs, thus enabling their implementation on the classical low molecular as well as on the new protein drugs. The development of validated numeric model of two-phase particles flow inside the coating process equipment is necessary to understand the results of coating process and also gives an insight into those parts of process chamber which can not be easily reached by experimental techniques. The numerical model of particles flow is additionally important as it represents a useful tool for planning and development of innovative coating process equipment. Development and optimization of technological procedures lead to the production of new delivery systems which enable us to control drug release and increase bioavailability of selected drugs. In this context solid peroral dosage forms on the basis of S(M)EDS were developed. This delivery system possesses all advantages of microemulsions together with increased stability and higher incorporation efficiency of model drugs. With the optimization of technological processes the applicability of these systems, which are limited to liquid systems and soft gelatin capsules till now, increases significantly. With the development of delivery systems like nanoparticles the efficacy of the therapy might be increased significantly and drugs’ adverse effects decreased. The results of our research work give us important information about interactions between different macromolecules (polymers and proteins) and show us how to apply the rules valid in natural biological systems (molecular interactions, spontaneous conformation, biological recognition, cell processes) for the preparation of new drug delivery systems. The possibilities how to circumvent the limitations and take the advantages of protein drugs when incorporating them in delivery systems were explored. The contemporary scientific trends are followed also in the field of studying LADME processes to identify those critical physico-chemical and biological parameters that influence the safety and efficacy of medicines. The experimental models of diversified degree of complexity which were developed in accordance with the goal of our researches are of key importance. Our aims were followed considering all processes to which the drug is exposed after different modes of application. With the development of in vitro tests, which enable us to describe the processes of drug release and absorption in in vivo conditions after fasted or fed administration, a significant contribution to further development of BCS system was given and by experimental approaches for description and prediction of presystemic metabolism one of its main deficiencies was clarified. Physiological parameters were introduced in the dissolution models to give common applicative approach additional scientific dimension and the results of permeability studies enable us a new insight in the mechanisms of mucosal transport of all studied types of drugs. Pharmacokinetic-pharmacodynamic models combined with the methods of population pharmacokinetics help us to identify the reasons for variability in pharmacokinetics, pharmacodynamics and consequently in clinical outcomes. By the use of this technique, the introduction of appropriate procedures before the start of therapy, like avoidance of drug interactions, assessment of genetic polymorphism of transport and metabolic systems, consideration of demographic and clinical-biochemical factors, were proposed. These studies represent most interesting scientific trends in the process of drug dosing optimization, especially if they are combined, as in our case, with monitoring economic and humanistic outcomes.
Significance for the country
The results of the proposed research program are important for the Slovenian pharmaceutical industry as well as for the Slovenian health care system, which have to follow the modern regulatory requests (EMA, FDA) for introducing the new technologies and application routes which will assure safe, effective and qualitative drug products and their rational use. Peptides and protein drugs are connected with high specificity, potency and effectiveness in small doses which will have a great impact on the human therapy in the near future. However, their use in the clinical praxis is more or less limited because of the unacceptable biopharmaceutical properties. These properties are a consequence of large molecular weight, hidrophylicity, complex and labile structure and reduce the use of already approved drugs to the parenteral route. This therapy is dealing with frequent dosing, additionally systemic adverse/toxic effect, lower patient compliance and higher costs. All these shortcomings are the driving forces for the pharmaceutical research regarding the development of new drug delivery systems, especially nanosystems. Slovenian pharmaceutical industry is able, due to its high technological level, to implement knowledge developed in this program into the pharmaceutical products with a very high added value. Proposed research program includes also some new technology strategies which mean challenge for the Slovenian process technology industry as well. The optimized technology processes together with the quality of the input ingredients, drugs and excipients, represent imperative for the quality of the drug products. Inside of the program also the aspects of the rationality in the energy and the materials use are considered and implemented. Proposed research program will also assure the knowledge which is important for sustainability of Slovenian health care systems in the fields of drug usage and utilization. Pharmacoepidemiological and pharmacoeconomic studies are included in wider context of health economics and are therefore of national importance.
Most important scientific results Annual report 2009, 2010, 2011, 2012, final report, complete report on dLib.si
Most important socioeconomically and culturally relevant results Annual report 2009, 2010, 2011, 2012, final report, complete report on dLib.si
Views history